Docetaxel and gemcitabine combination as first-line treatment in advanced or metastatic non-small-cell lung cancer: A multicenter phase II study

被引：0
|
作者：
Costa, A [1 ]
Almodovar, T [1 ]
Seada, J [1 ]
Barata, F [1 ]
Teixeira, E [1 ]
Queiroga, H [1 ]
Pires, S [1 ]
机构：
[1] Hosp Pulido Valente, Lisbon, Portugal
来源：
PROCEEDINGS OF THE 9TH CENTRAL EUROPEAN LUNG CANCER CONFERENCE | 2004年
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The combination of docetaxel and gemcitabine is an active 1(st) line chemotherapy against NSCLC. This phase II study aimed to assess the efficacy and safety of this combination in patients with stage IIIB/IV NSCLC. Pts were treated with gemcitabine 800 mg/m(2) dl, d8 and docetaxel 85 mg/m(2) d8, q3w. 34 pts were enrolled. PR was observed in 8 pts (25.8%; 95% CI, 10.4%-41.2%), SD in 16 (51.6%) and PD in 7 (22.6%). The median duration of response and the TTP were 8.9 and 5.3 months, while the median survival time was 10.9 months. The 1 and 2-year survival rates were 45% and 18%. Most toxicities were mild and nonhematologic. Neutropenia G3/4 occurred in 6 (17,6%) pts. In conclusion combination therapy with docetaxel and gemcitabine is an effective and well-tolerated (1st) line treatment option in pts with stage IIIB/IV NSCLC.
引用
收藏
页码：117 / 120
页数：4
相关论文
共 50 条
  • [21] A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer
    Mori, Kiyoshi
    Kobayashi, Hiroyuki
    Kamiyama, Yukari
    Kano, Yasuhiko
    Kodama, Tetsuro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (01) : 73 - 78
  • [22] First-line treatment for advanced non-small-cell lung cancer
    Laskin, Janessa J.
    Sandler, Alan B.
    ONCOLOGY-NEW YORK, 2005, 19 (13): : 1671 - 1676
  • [23] A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer
    Kiyoshi Mori
    Hiroyuki Kobayashi
    Yukari Kamiyama
    Yasuhiko Kano
    Tetsuro Kodama
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 73 - 78
  • [24] Phase II study of the combination of gemcitabine and nedaplatin for advanced non-small-cell lung cancer
    Shirai, T
    Hirose, T
    Noda, M
    Ando, K
    Lshida, H
    Hosaka, T
    Ozawa, T
    Okuda, K
    Ohnishi, T
    Ohmori, T
    Horichi, N
    Adachi, M
    LUNG CANCER, 2006, 52 (02) : 181 - 187
  • [25] First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study
    Tibaldi, C.
    Vasile, E.
    Antonuzzo, A.
    Di Marsico, R.
    Fabbri, A.
    Innocenti, F.
    Tartarelli, G.
    Amoroso, D.
    Andreuccetti, M.
    Lo Dico, M.
    Falcone, A.
    BRITISH JOURNAL OF CANCER, 2008, 98 (03) : 558 - 563
  • [26] First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study
    C Tibaldi
    E Vasile
    A Antonuzzo
    R Di Marsico
    A Fabbri
    F Innocenti
    G Tartarelli
    D Amoroso
    M Andreuccetti
    M Lo Dico
    A Falcone
    British Journal of Cancer, 2008, 98 : 558 - 563
  • [27] First line chemotherapy with sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer (NSCLC) patients: A multicenter phase II study
    Lo Dico, M.
    Vasile, E.
    Tibaldi, C.
    Antonuzzo, A.
    Di Marsico, R.
    Tartarelli, G.
    Fabbri, A.
    Mazzoni, E.
    Andreuccetti, M.
    D'Alessandro, M.
    Nacci, A.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 35 - 35
  • [28] A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC)
    Luis E. Raez
    Edgardo S. Santos
    R. Timothy Webb
    James Wade
    Roger A. Brito
    Melissa Karr
    Andra Kennah
    Barrett H. Childs
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 1103 - 1110
  • [29] A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC)
    Raez, Luis E.
    Santos, Edgardo S.
    Webb, R. Timothy
    Wade, James
    Brito, Roger A.
    Karr, Melissa
    Kennah, Andra
    Childs, Barrett H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (05) : 1103 - 1110
  • [30] GEMCITABINE-DOCETAXEL VERSUS CISPLATIN-GEMCITABINE AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC NON-SMALL-CELL LUNG CANCER
    Al-Gizawy, S. M.
    Mostafa, H. G.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : E15 - E15
12345